Diabetes Monograph/Newsletter Program

The Diabetes Monograph/Newsletter program consists of newsletters and tests presented twice a year based on highlights from the meetings below

Developed by Robert S. Sherwin MD and Silvio E. Inzucchi MD, of the Yale School of Medicine Endocrinology Section of Internal Medicine, the Diabetes Monograph/Newsletter program is a series of daily newsletters summarizing the latest scientific data and information on diabetes presented during the two leading international diabetes scientific meetings mentioned above. This series provides physicians with valuable information regardless of whether they attend the meetings.

Presently, these newsletters are emailed to participants daily during these meetings. Shortly after the meetings conclude, participants will receive a Diabetes monograph via email. The most current newsletters and monographs are available in the left column of this page. Upon successful completion of the Diabetes quiz, physicians can earn up to 5.0 AMA PRA Category 1 creditsTM.

To begin receiving the FREE monograph and newsletters, please click here. 

To unsubscribe from this Diabetes program, please click here.

Newsletter Archives

Click here to see past Newsletters.

Needs and Objectives

Educational Needs

This program seeks to provide physicians with the latest and most important information presented at recent scientific meetings. Unfortunately, despite the valuable information that can be gained at these conferences, the majority of practicing physicians are unable to attend them. And, given the size and scope of these meetings, attendees often miss data presentations of interest to them. Therefore, programs designed to disseminate information from these meetings on a timely basis to physicians who either cannot attend the conference or who miss some of the presentations fulfill an educational need that would otherwise not be met.

Learning Objectives

At the conclusion of this program, the participant should be able to:

  • Explain the pathogenesis of Type 2 diabetes, especially the coexisting roles of insulin resistance and insulin secretion.
  • Describe the evolving cellular mechanisms associated with beta cell failure, the progression of diabetes, and its complications.
  • Implement strategies for the early diagnosis and treatment of diabetes.
  • Recognize the clinical manifestations of the macrovascular and microvascular complications of diabetes and describe appropriate therapeutic interventions.
  • Recognize the interrelationship between insulin resistance, hyperglycemia, and atherosclerosis in patients with Type 2 diabetes.
  • Compare the mechanisms of actions of the various pharmacologic agents for the treatment of diabetes, their risks and benefits, and their proper role in the management of this disease.
  • Identify evolving and emerging management strategies for diabetes (e.g., combination therapies, new insulin delivery systems, new glucose monitoring techniques, novel drugs.)
  • Describe the approach to managing dyslipidemia, hypertension, and cardiovascular risk factors in patients with diabetes.
  • Identify unique management issues among special sub-populations of patients with diabetes.
  • Discuss the impact of diabetes on the healthcare system.


Disclosure Policy

It is the policy of Yale School of Medicine, Continuing Medical Education, to ensure balance, independence, objectivity and scientific rigor in all its educational programs. All participants in this program are required to disclose any relevant financial relationship(s) they (or spouse/partner) have with a commercial interest that benefits the individual in any financial amount that has occurred within the past 12 months; and the opportunity to affect the content of CME about the products or services of the commercial interests. The Center for Continuing Medical Education will ensure that any conflicts of interest are resolved prior to this activity.


In meeting the requirements of full disclosure and in compliance with the Accreditation Council for Continuing Medical Education Essentials, Standards for Commercial Support, and Guidelines, the following information has been provided by our editors regarding potential conflicts of interest: Robert S. Sherwin, M.D. is engaged in research activities supported by Bayer, Chiron, Eli Lilly and Company, Novartis Pharmaceuticals Corporation, Pfizer Inc., and Takeda Pharmaceuticals North America, Inc. Silvio E. Inzucchi, M.D. is a consultant to Aventis, Eli Lilly and Company, Novartis Pharmaceuticals Corporation, GlaxoSmithKline, and Takeda Pharmaceuticals America, Inc. In accordance with the 2004 ACCME Standards for Commercial Support, a peer review process has been established for this program and all Conflict of Interest issues (if any) have been resolved.


This CME program is supported in part through educational grants from 

Boehringer Ingelheim Pharmaceuticals, Inc., 

Eli Lilly and Company, 

Merck & Co., Inc. and Sanofi.

Target Audience

Invited participants are cardiologists and physicians who have a primary interest in and care for patients with Type 2 diabetes.

Educational Methods

Fax and Email: At the end of each conference day, a newsletter will be faxed or sent by e-mail to the office of subscribing physicians. Shortly after each conference concludes, participants will receive a Diabetes monograph via email for the conference containing all of the newsletters and a program highlights summary from the program co-editors. CME credits can be obtained on the Yale CME website.

On-Line: At the end of each conference day, the newsletter will be downloaded to the Yale CME web site where subscribers may view the information and, if they desire, obtain CME credits on line. 


A course evaluation form will provide participants with the opportunity to review the program content and method of delivery and to identify future educational needs and possible bias in the presentation.


This program has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the sponsorship of Yale University School of Medicine.

The Yale School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to sponsor continuing medical education for physicians.

The American Medical Association has determined that physicians not licensed in the US who participate in the CME activity are eligible for AMA PRA Category 1 Credit™.

Designation Statement

The Yale School of Medicine designates this educational activity for a maximum of 5.0 AMA PRA Category 1 Credits™ per monograph. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Performance Improvement CME Credit

Yale CME is no longer offering Performance Improvement activities.